Text Size

Safety and Effectiveness of the PRESERFLO® MicroShunt in Primary Open-Angle Glaucoma: Results from a 2-Year Multicenter Study

Beckers HJM, Aptel F, Webers CAB, Bluwol E, Martínez-de-la-Casa JM, García-Feijoó J, Lachkar Y, Méndez-Hernández CD, Riss I, Shao H, Pinchuk L, Angeles R, Sadruddin O, Shaarawy TM.


  • 2021
  • Ophthalmology Glaucoma
View publication
  • Therapeutic Area

    Glaucoma

  • Categories

    Clinical development

  • Affiliations

    University Eye Clinic, Maastricht University Medical Center, Maastricht, the Netherlands; CHU de Grenoble-Alpes, Grenoble, France; University Eye Clinic, Maastricht University Medical Center, Maastricht, the Netherlands; Hôpital Paris Saint Joseph, Paris, France; Departamento de Oftalmologia Universidad Complutense, Hospital Clínico San Carlos, OFTARED, Madrid, Spain; Pôle Ophtalmologique de la Clinique Mutualiste, Bordeaux, France; Santen Inc., Emeryville, California; InnFocus Inc., a Santen Company, Miami, Florida; Hôpitaux Universitaires de Genève, Geneva, Switzerland

Related Publications

Clinical outcomes of Preserflo MicroShunt implant procedure in open‑angle glaucoma patients – a 1000 eyes case-series; including subanalysis of combined cataract-glaucoma surgery and standalone surgery in pseudophakic eyes

Klabe, K.; Werth, J.P.; Kaymak, H. ; Fricke, A.


Müller glia derived EVs promote neurite recovery of an enriched population of retinal ganglion like cells derived from hESC retinal organoids after damage

Eastlake K, Lamb WDB, Tracey-White D, Shibagaki K, Khaw PT, Jayaram H, Limb GA


An Exploratory Study of Machine Learning-Based Open-Angle Glaucoma Detection Using Specific Autoantibodies

Takada N., Ishikawa M., Ninomiya T., Izumi Y., Sato K., Kunikata H., Yokoyama Y., Tsuda S., Fukuda E., Yamaguchi K., Ono C., Kirihara T., Shintani C., Hanyuda A., Goshima N., Zorumski C.F., NakazawaT.


Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022